This page is intended as reference information for the general public.
What is COMIRNATY and what is it used for?
COMIRNATY is a vaccine that has been developed by BioNTech and Pfizer.
COMIRNATY has the following indications:
COMIRNATY 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older.1,2
COMIRNATY 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years.3,4
COMIRNATY 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 6 months to 4 years.5,6
The vaccine triggers the body’s natural production of antibodies and stimulates immune cells to help protect against COVID-19 disease.
Reporting Side Effects
As with any new medicine in the UK, this product will be closely monitored to allow quick identification of new safety information. You can help by reporting any side effects that you may get. To report any side effects that you may get, please refer to the information at the bottom of this page.
The information provided on this site is intended for general information and education for UK based members of the public and is not intended to be a substitute for advice provided by a doctor or other qualified healthcare professional.
Reference Information
Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for COMIRNATY please follow these links:
Great Britain
COMIRNATY 30 micrograms/dose concentrate for dispersion for injection
COMIRNATY 10 micrograms/dose concentrate for dispersion for injection
COMIRNATY 3 micrograms/dose concentrate for dispersion for injection
Northern Ireland
COMIRNATY 30 micrograms/dose concentrate for dispersion for injection
COMIRNATY 10 micrograms/dose concentrate for dispersion for injection
COMIRNATY 3 micrograms/dose concentrate for dispersion for injection
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://coronavirus-yellowcard.mhra.gov.uk for how to report side effects.
Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.
If you are concerned about a side-effect it can be reported directly via the Coronavirus Yellow Card reporting site https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. When completing a report please include the vaccine brand and batch/lot number if available.
References
COMIRNATY® (tozinameran) 30 micrograms/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) Summary of Product Characteristics, Great Britain. Available here. Accessed Feb 2023.
COMIRNATY® (tozinameran) 30 micrograms/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) Summary of Product Characteristics, Northern Ireland. Available here. Accessed Feb 2023.
COMIRNATY® (tozinameran) 10 micrograms/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) Summary of Product Characteristics, Great Britain. Available here. Accessed Feb 2023.
COMIRNATY® (tozinameran) 10 micrograms/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) Summary of Product Characteristics, Northern Ireland. Available here. Accessed Feb 2023.
COMIRNATY® (tozinameran) 3 micrograms/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) Summary of Product Characteristics, Great Britain. Available here. Accessed Feb 2023.
COMIRNATY® (tozinameran) 3 micrograms/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) Summary of Product Characteristics, Northern Ireland. Available here. Accessed Feb 2023.